<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910689</url>
  </required_header>
  <id_info>
    <org_study_id>2R01NS032374</org_study_id>
    <secondary_id>NS32374</secondary_id>
    <nct_id>NCT00910689</nct_id>
  </id_info>
  <brief_title>Drug and Non-Drug Treatment Of Severe Migraine</brief_title>
  <acronym>TSM</acronym>
  <official_title>Drug and Non-Drug Treatment of Severe Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the addition of preventive medication, behavior
      migraine management or the combination of preventive medication and behavior migraine
      management improves the outcome of optimal acute therapy for frequent migraines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the 5 week Optimal Acute Therapy (OAT) Run in (Month 1) all participants who met
      initial inclusion criteria received &quot;optimal&quot; acute therapy (OAT). At the end of the OAT
      Run-in, participants who continued to meet the migraine severity criteria were stratified by
      sex and randomized via a computerized randomization procedure to the four added treatments:
      Beta Blocker Placebo (PL), Beta Blocker (Propranolol LA or Nadolol), Behavioral Migraine
      Management (BMM) + PL, or BMM + Beta Blocker. Each of the 4 treatment protocols required 4
      monthly clinic visits and 3 telephone contacts during the 3 month Treatment/Dose Adjustment
      Phase (Month 2 to Month 4) where Beta Blocker or PL dose was adjusted and BMM was
      administered. During the 12 month (Month 5 to Month 16) Evaluation Phase clinic visits were
      scheduled at Month 5, Month 7, Month 10 (the Primary End Point), Month 13 and Month 16.
      Treatment conditions were blinded only for the preventive medication (Beta Blocker, Placebo)
      component, and not for the administration of BMM. Electronic headache diary recordings are
      obtained for the full 16 months of the trial, including the 12 month evaluation phase, and
      migraine-related impairments in quality of life are assessed at multiple points over the 16
      months of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Migraine Episodes Per 30 Days at Month 10.</measure>
    <time_frame>Change from Month 1 to Month 10</time_frame>
    <description>Change in number of migraine episodes(with 24 hours pain free period required between episodes)per 30 days from OAT run-in (Month 1) to Month 10.Obtained from daily electronic diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Migraine Days Per 30 Days at Month 10</measure>
    <time_frame>Change from Month 1 to Month 10</time_frame>
    <description>Change in the number of days with migraine per 30 days at Month 10 relative to the OAT Run-in (Month 1). Obtained from daily electronic diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life at Month 10</measure>
    <time_frame>Change from Month 1 to Month 10</time_frame>
    <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores at Month 10 relative to OAT run-in (Month 1). The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Migraine Episodes Per 30 Days at Month 16.</measure>
    <time_frame>Change from Month 1 to Month 16</time_frame>
    <description>Change in number of migraine episodes (with 24 hours pain free period required between episodes) per 30 days from OAT run-in (Month 1) to Month 16. Assessed by participant daily electronic diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Migraine Days Per 30 Days at Month 16</measure>
    <time_frame>Change form Month 1 to Month 16</time_frame>
    <description>Change in the number of migraine days per 30 days at Month 16 relative to the OAT run-in (Month 1). Assessed by participant electronic diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life at Month 16</measure>
    <time_frame>Change from Month 1 to Month 16</time_frame>
    <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores relative to OAT run-in. The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol or nadolol</intervention_name>
    <description>Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Inderal</other_name>
    <other_name>Nadolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Migraine Management (BMM)</intervention_name>
    <description>Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with &quot;basic&quot; migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (&quot;hand warming&quot;) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Behavioral Treatment</other_name>
    <other_name>BMM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Acute Therapy</intervention_name>
    <description>This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Imitrex®</other_name>
    <other_name>Maxalt®</other_name>
    <other_name>Reglan®</other_name>
    <other_name>Advil®</other_name>
    <other_name>Motrin®</other_name>
    <other_name>Nuprin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years

          -  Diagnosis of migraine with or without aura (International Classification of Headache
             Disorders)

          -  3 or more migraine episodes/month with disability for the past 6 months

          -  Less than 20 total headache days/month for the past 6 months

        Exclusion Criteria:

          -  Medication overuse headaches

          -  Currently taking medications contraindicated by study protocol and unable or unwilling
             to withdraw

          -  Concurrently undergoing counseling/psychotherapy treatment

          -  Unable to read, understand or record information in study diaries, questionnaires, and
             migraine management manual.

          -  Unable/unwilling to give written informed consent

          -  History of exclusionary medical condition such as, but not limited to, epilepsy, heart
             disease, kidney disease, liver disease, hepatic or renal impairment, stroke, ischemic
             abdominal syndromes, peripheral vascular disease.

          -  Uncontrolled hypertension at screening (sitting systolic pressure &gt; 160 mmHg,
             diastolic pressure &gt; 95 mmHg)

          -  Fertile female who is breastfeeding, pregnant planning a pregnancy within the next
             year or is unwilling to use adequate contraception.

          -  Has exclusionary medical condition such as but not limited to diabetes (insulin
             dependent), tuberculosis, bronchospastic disease (asthma), heart disease (or multiple
             risk factors for heart disease), angina pectoris, documented silent ischemia, or
             cardiac arrythmias requiring medication, or a clinically significant EKG abnormality.

          -  Other pain diagnosis is primary presenting problem (e.g., fibromyalgia)

          -  Has a substance abuse problem or a psychological disorder that prevents participation
             in study (e.g., unmanaged severe depression that requires immediate treatment or
             limits participation in home-based treatment)

          -  Hypersensitivity, intolerance or contraindication to use of Propranolol, Nadolol,
             Sumatriptan, or Rizatriptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth A Holroyd, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio University</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoNeuro, Inc.</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000 Mar;40(3):204-15.</citation>
    <PMID>10759923</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <results_first_submitted>November 24, 2008</results_first_submitted>
  <results_first_submitted_qc>April 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 1, 2009</results_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <name_title>Kenneth Holroyd, Distinguished Professor. Department of Psychology</name_title>
    <organization>Ohio University</organization>
  </responsible_party>
  <keyword>Migraine Headache</keyword>
  <keyword>Preventive Therapy</keyword>
  <keyword>Beta Blocker Medication</keyword>
  <keyword>Behavior Therapy</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Nadolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatient clinics</recruitment_details>
      <pre_assignment_details>5 week Optimal Acute Therapy (OAT) Run in (M1) precedes random assignment (see detailed design description).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OAT + Placebo (PL)</title>
          <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
        </group>
        <group group_id="P2">
          <title>OAT + Beta Blocker (Beta-B)</title>
          <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
        </group>
        <group group_id="P3">
          <title>OAT + BMM + PL</title>
          <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
        </group>
        <group group_id="P4">
          <title>OAT + BMM + Beta-B</title>
          <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 1: Optimal Acute Therapy Run in</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Post OAT Run-in data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 2- 4: Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time Demands</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Perceived Improvement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Months 5 - 10: Evaluation Period I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time Demands</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Months 11- 16: Evaluation Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time Demands</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Perceived Improvement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OAT + Placebo (PL)</title>
          <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
        </group>
        <group group_id="B2">
          <title>OAT + Beta Blocker (Beta-B)</title>
          <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
        </group>
        <group group_id="B3">
          <title>OAT + BMM + PL</title>
          <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
        </group>
        <group group_id="B4">
          <title>OAT + BMM + Beta-B</title>
          <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="69"/>
            <count group_id="B5" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="10.2"/>
                    <measurement group_id="B2" value="37.7" spread="10.1"/>
                    <measurement group_id="B3" value="37.1" spread="9.4"/>
                    <measurement group_id="B4" value="38.3" spread="10.9"/>
                    <measurement group_id="B5" value="38.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Migraine Episodes Per 30 Days at Month 10.</title>
        <description>Change in number of migraine episodes(with 24 hours pain free period required between episodes)per 30 days from OAT run-in (Month 1) to Month 10.Obtained from daily electronic diary.</description>
        <time_frame>Change from Month 1 to Month 10</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Migraine Episodes Per 30 Days at Month 10.</title>
          <description>Change in number of migraine episodes(with 24 hours pain free period required between episodes)per 30 days from OAT run-in (Month 1) to Month 10.Obtained from daily electronic diary.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Number of Migraine episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-2.2" upper_limit="-1.9"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-2.2" upper_limit="-1.9"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-2.4" upper_limit="-2.0"/>
                    <measurement group_id="O4" value="-3.3" lower_limit="-3.5" upper_limit="-3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Omnibus Test: A mixed model with fixed effects for treatment,natural time(defined as natural log of months) and treatment-by-time interaction was used to obtain maximum likelihood estimates of missing values and to evaluate treatment effects(using the PROC MIXED procedure in SAS statistical software,version 9;www.sas.com). A significant treatment by time interaction(p &lt; .05, 2-tailed) was followed by post-tests (see below). Details of significant post tests are reported as separate analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .01</p_value>
            <p_value_desc>Post tests consisted of 6 pair wise contrasts: The first 3 contrasts compared each of the 3 additive treatments (Trial Arms 2, 3, 4) to OAT + PL (Trial arm 1); 3 additional contrasts compared the 3 additive treatments to one another.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A Bonferoni procedure was used to control the family-wise type I error for the 6 post test contrasts at .05. Adjusted p =.0083.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .25</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .98</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 120.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.29</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Number of Migraine Days Per 30 Days at Month 10</title>
        <description>Change in the number of days with migraine per 30 days at Month 10 relative to the OAT Run-in (Month 1). Obtained from daily electronic diary.</description>
        <time_frame>Change from Month 1 to Month 10</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Migraine Days Per 30 Days at Month 10</title>
          <description>Change in the number of days with migraine per 30 days at Month 10 relative to the OAT Run-in (Month 1). Obtained from daily electronic diary.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Number of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-3.6" upper_limit="-3.0"/>
                    <measurement group_id="O2" value="-3.9" lower_limit="-4.2" upper_limit="-3.5"/>
                    <measurement group_id="O3" value="-3.3" lower_limit="-3.7" upper_limit="-2.9"/>
                    <measurement group_id="O4" value="-5.4" lower_limit="-5.6" upper_limit="-5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Omnibus test:A mixed model with fixed effects for treatment, time (defined as the natural log of months), and the treatment-by-time interaction was used to obtain maximum likelihood estimates of missing values and to evaluate treatment effects (PROC MIXED, SAS 9).When the treatment by time interaction was significant (p &lt; .05, 2-tailed)post-tests were conducted (see below).Details of significant post tests are reported as separate analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .03</p_value>
            <p_value_desc>6 pair wise contrasts were conducted: The first 3 contrasts compared each of the 3 additive treatments to OAT + PL. The 3 additional contrasts compared the 3 additive treatments to one another.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A Bonferoni procedure was used to control the family wise type I error for the 6 post test contrasts at .05. Adjusted p =.0083.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .02</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.79</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.35</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.02</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.43</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life at Month 10</title>
        <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores at Month 10 relative to OAT run-in (Month 1). The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
        <time_frame>Change from Month 1 to Month 10</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life at Month 10</title>
          <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores at Month 10 relative to OAT run-in (Month 1). The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" lower_limit="-7.8" upper_limit="-6.3"/>
                    <measurement group_id="O2" value="-7.1" lower_limit="-7.7" upper_limit="-6.6"/>
                    <measurement group_id="O3" value="-8.6" lower_limit="-8.9" upper_limit="-8.2"/>
                    <measurement group_id="O4" value="-13.0" lower_limit="-13.5" upper_limit="-12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Omnibus test:A mixed model with fixed effects for treatment, time (defined as the natural log of months), and the treatment-by-time interaction and pretreatment Migraine Specific Quality of Life scores as covariate was used to obtain maximum likelihood estimates of missing values and to evaluate treatment effects (using the PROC MIXED procedure in SAS statistical software, version 9; www. sas.com).A significant treatment by time interaction (p &lt; .05, 2-tailed) was followed by post-tests</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.005</p_value>
            <p_value_desc>Post tests consisted of 6 pair wise contrasts: The first 3 contrasts compared each of the 3 additive treatments (Trial Arms 2, 3, 4) to OAT + PL (Trial arm 1); three additional contrasts compared the 3 additive treatments to one another.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>A Bonferoni procedure controlled the familywise type I error for the 6 contrasts at .05. Adjusted p=.0083.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 120.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.87</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.38</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Migraine Episodes Per 30 Days at Month 16.</title>
        <description>Change in number of migraine episodes (with 24 hours pain free period required between episodes) per 30 days from OAT run-in (Month 1) to Month 16. Assessed by participant daily electronic diary.</description>
        <time_frame>Change from Month 1 to Month 16</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Migraine Episodes Per 30 Days at Month 16.</title>
          <description>Change in number of migraine episodes (with 24 hours pain free period required between episodes) per 30 days from OAT run-in (Month 1) to Month 16. Assessed by participant daily electronic diary.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Number of Migraine Episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-2.6" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-2.8" upper_limit="-2.2"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-2.9" upper_limit="-2.5"/>
                    <measurement group_id="O4" value="-3.8" lower_limit="-4.0" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .83</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Significant post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 120.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.95</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; .20</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Number of Migraine Days Per 30 Days at Month 16</title>
        <description>Change in the number of migraine days per 30 days at Month 16 relative to the OAT run-in (Month 1). Assessed by participant electronic diary.</description>
        <time_frame>Change form Month 1 to Month 16</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Migraine Days Per 30 Days at Month 16</title>
          <description>Change in the number of migraine days per 30 days at Month 16 relative to the OAT run-in (Month 1). Assessed by participant electronic diary.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-4.3" upper_limit="-3.5"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-5.1" upper_limit="-4.0"/>
                    <measurement group_id="O3" value="-4.1" lower_limit="-4.5" upper_limit="-3.8"/>
                    <measurement group_id="O4" value="-6.1" lower_limit="-6.6" upper_limit="-5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 120.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.04</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.69</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.33</p_value>
            <p_value_desc>Bonerfoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.34</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.21</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life at Month 16</title>
        <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores relative to OAT run-in. The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
        <time_frame>Change from Month 1 to Month 16</time_frame>
        <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
        <group_list>
          <group group_id="O1">
            <title>OAT + Placebo (PL)</title>
            <description>Optimal Acute Therapy plus Beta Blocker Placebo</description>
          </group>
          <group group_id="O2">
            <title>OAT + Beta Blocker (Beta-B)</title>
            <description>Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)</description>
          </group>
          <group group_id="O3">
            <title>OAT + BMM + PL</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus placebo</description>
          </group>
          <group group_id="O4">
            <title>OAT + BMM + Beta-B</title>
            <description>Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life at Month 16</title>
          <description>Change in Migraine Specific Quality of Life Questionnaire (MSQL; Martin, et al., 2000: v 2.1) scores relative to OAT run-in. The MSQL is a 14-item self-report measure that assesses the impact of migraine. The total score ranges from 14 to 84 with higher scores reflecting greater impairment.</description>
          <population>Efficacy analyses were intent-to-treat analyses that included all randomized (N = 232) participants.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" lower_limit="-9.5" upper_limit="-8.1"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-9.4" upper_limit="-7.6"/>
                    <measurement group_id="O3" value="-9.6" lower_limit="-10.3" upper_limit="-9.0"/>
                    <measurement group_id="O4" value="-15.2" lower_limit="-16.0" upper_limit="-14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .001</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 122.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.56</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.85</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.08</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 108.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Post-test contrast. Mean difference in change.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.03</p_value>
            <p_value_desc>Bonferoni adjusted critical value p = .0083.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Degrees of freedom = 1 and 106.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.83</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OAT + Placebo (PL) at Month 5</title>
          <description>Optimal Acute Therapy (OAT) + Beta-Blocker (Propranolol/ Nadolol)Placebo. Side-effects (Fatigue, Gastrointestinal Distress, Insomnia, Lightheaded or Dizzy, Difficulty Concentrating, Depression, Weight Gain, Exercise Intolerance, Nightmares, Drowsiness or Other side effect at Month 5 following dose adjustment.</description>
        </group>
        <group group_id="E2">
          <title>OAT + Beta-Blocker at Month 5</title>
          <description>Optimal Acute Therapy (OAT) + Beta-Blocker (Propranolol/Nadolol. Side-effects (Fatigue, Gastrointestinal Distress, Insomnia, Lightheaded or Dizzy, Difficulty Concentrating, Depression, Weight Gain, Exercise Intolerance, Nightmares, Drowsiness or other side-effect assessed after dose adjustment(Month 5).</description>
        </group>
        <group group_id="E3">
          <title>OAT + BMM + PL at Month 5</title>
          <description>Optimal Acute Therapy + Behavioral Migraine Management(BMM) + Beta-Blocker(Propranolol/Nadolol) Placebo.
Side-effects (Fatigue, Gastrointestinal Distress, Insomnia, Lightheaded or Dizzy, Difficulty Concentrating, Depression, Weight Gain, Exercise Intolerance, Nightmares, Drowsiness or other side-effect)as assessed after dose adjustment(Month 5).</description>
        </group>
        <group group_id="E4">
          <title>OAT + BMM + Beta-Blocker at Month 5</title>
          <description>Optimal Acute Therapy (OAT)+ Behavioral Migraine Management (BMM)+ Beta-Blocker(Propranolol/Nadolol).
Side-effects (Fatigue, Gastrointestinal Distress, Insomnia, Lightheaded or Dizzy, Difficulty Concentrating, Depression, Weight Gain, Exercise Intolerance, Nightmares, Drowsiness or other side effect) assessed after dose adjustment(Month 5).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="7"/>
                <counts group_id="E3" subjects_affected="2"/>
                <counts group_id="E4" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No side effect reached the 5% reporting threshold at either the Month 10 or the Month 16 assessment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kenneth Holroyd</name_or_title>
      <organization>Ohio University</organization>
      <phone>(740) 593-1085</phone>
      <email>holroyd@ohio.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

